Allopurinol-Induced Toxic Epidermal Necrolysis Following A Sub-Minimal Starting Dose: A Multidisciplinary Management Challenge

Main Article Content

Ana Sophia Ortiz Robles*
Victoria López Estudillo
Andreina Magaly Moreno Román
Araceli Ingrid Alonso Arias
Cynthia Zendejas Garibay
Flavio Antonio Sarabia Alba
Miriam Ericka Villanueva Carmolinga
Lizbeth Guadalupe Hernández Pulido

Abstract

Toxic Epidermal Necrolysis (TEN) is a rare, severe mucocutaneous drug reaction within a single clinical spectrum, distinguished by epidermal detachment involving>30% of body surface area (BSA). Allopurinol is among the most common causative agents, particularly in patients newly started on therapy, and carries a well-established pharmacogenomic association with the HLA-B*58:01 allele. We present the case of a 55-year-old woman with newly diagnosed hyperuricemia who developed generalized pruritus within hours of taking half of a 300-mg allopurinol tablet, followed by burning in the bilateral axillary and inguinal regions and erythema of the trunk and abdomen. Within hours, she developed flaccid bullae with a positive Nikolsky sign, together with periorbital, conjunctival, oral, and vulvovaginal mucosal involvement. She was admitted to the intensive care unit with a diagnosis of Stevens-Johnson syndrome, an initial epidermal detachment under 10% of body surface area, and a SCORTEN of 1 (predicted mortality 3.2%). Gynecology was consulted for vulvovaginal ulceration and atrophic mucosa. Cutaneous detachment progressed to involve approximately 40-50% of BSA, requiring three staged surgical washouts and debridements with application of a porcine-derived extracellular matrix wound dressing to promote re-epithelialization. The hospital course was further complicated by transient vasopressor-requiring hypotension, chronic hypo-osmolar hyponatremia, probable relative adrenal insufficiency following corticosteroid tapering, opioid-associated ileus, and recurrent hypoglycemia, all managed supportively without evidence of superimposed infection. After 15 days in the intensive care unit, the patient was transferred to the internal medicine ward with favorable re-epithelialization of cutaneous lesions and resolution of cervicovaginitis. This case illustrates the fast development and multisystem nature of allopurinol-induced SJS/TEN overlap and the value of early, protocolized multidisciplinary management.

Article Details

How to Cite
Ortiz Robles*, Ana Sophia, Victoria López Estudillo, Andreina Magaly Moreno Román, Araceli Ingrid Alonso Arias, Cynthia Zendejas Garibay, Flavio Antonio Sarabia Alba, Miriam Ericka Villanueva Carmolinga, and Lizbeth Guadalupe Hernández Pulido. 2026. “Allopurinol-Induced Toxic Epidermal Necrolysis Following A Sub-Minimal Starting Dose: A Multidisciplinary Management Challenge”. International Journal of Medical Science and Clinical Research Studies 6 (09):1912-17. https://doi.org/10.47191/ijmscrs/v6-i9-20.
Section
Articles

References

I. Shah H, Parisi R, Mukherjee E, Phillips EJ, Dodiuk-Gad RP: Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. Am J Clin Dermatol. 2024, 25:891-908. 10.1007/s40257-024-00889-6

II. Borjikhani S, Ebrahimpour S, Mohammadi M: Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Case Reports and Case Series. Dermatol Ther. 2025, 2025:6527730. 10.1155/dth/6527730

III. Pham HT, Tran MH, Hoang TM, Nguyen AH, Tran MH: HLA-B*58:01 genotyping prevalence and the association with allopurinol-induced severe cutaneous adverse reactions: a living systematic review and meta-analysis. Sci Rep. 2025, 15:30742. 10.1038/s41598-025-16062-w

IV. Strużyna J, Surowiecka A, Korzeniowski T, Korulczyk P, Drozd L, Stachura A, Torres K, Krajewski A: Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis. BMC Med Inform Decis Mak. 2022, 22:273. 10.1186/s12911-022-02013-2

V. Nazerian A, Jafarzadeh A, Salehi S, Ghasemi M, Goodarzi A: Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments. Inflammopharmacology. 2025, 33:485-503. 10.1007/s10787-024-01590-0

VI. DenAdel MA, Hendrickson SE, Fuchs E: Stevens Johnson Syndrome: Past, Present, and Future Directions Gynecologic Manifestations and Management in SJS/TEN. Front Med (Lausanne). 2022, 9:874445. 10.3389/fmed.2022.874445

VII. Chin LD, MacGillivary ML, Purdy KS, Kirshen C: Stevens-Johnson syndrome with overlapping features of DRESS syndrome: A report of two cases. SAGE Open Med Case Rep. 2024, 12:2050313X241307097. 10.1177/2050313X241307097

VIII. Lipkin I, Hughes M, Hughes WB: Utilization of Suprathel® in Delayed Surgical Management of Toxic Epidermal Necrolysis (TEN): A Case Report. Burns Open. 2025, 10:100399. 10.1016/j.burnso.2025.100399

IX. Sawires K, Tao BK, Nithianandan H, Menant-Tay L, O'Connor M, Yan P, Arjmand P: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Ophthalmic Management and Treatment. Vision (Basel). 2025, 9:78. 10.3390/vision9030078

X. Fredrick FC, Meda AKR, Singh B, Jain R: Critical illness-related corticosteroid insufficiency: latest pathophysiology and management guidelines. Acute Crit Care. 2024, 39:331-340. 10.4266/acc.2024.00647

XI. Li Y, Tu Y, Zhou Z, Liao D, He Z, Li Y, Li B, Liu Z, Zhou Z, Ai S: Efficacy and safety of opioid-receptor antagonists for opioid-induced constipation: a systematic review and meta-analysis. Front Pharmacol. 2026, 16:1749875. 10.3389/fphar.2025.1749875